A randomised controlled trial of modafinil for treatment of daytime somnolence in myotonic dystrophy

A randomised controlled trial of modafinil for treatment of daytime somnolence in myotonic dystrophy

Bibliographic Details
Main Authors:	Talbot, K, Stradling, J, Crosby, J, Hilton-Jones, D
Format:	Conference item
Published:	2003

Similar Items

Positive effect of modafinil on daytime somnolence on patients with Myotonic Dystrophy
by: Talbot, K, et al.
Published: (2002)

Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy.
by: Talbot, K, et al.
Published: (2003)

Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1--the patients' perspective.
by: Hilton-Jones, D, et al.
Published: (2012)

Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1 - The patients' perspective
by: Hilton-Jones, D, et al.
Published: (2012)

The myotonic dystrophies: diagnosis and management.
by: Turner, C, et al.
Published: (2010)

Molecular genetics of myotonic dystrophy.
by: Barnes, P, et al.
Published: (1993)

Myotonic dystrophy: diagnosis, management and new therapies.
by: Turner, C, et al.
Published: (2014)

Myotonic dystrophy--forgotten aspects of an often neglected condition.
by: Hilton-Jones, D
Published: (1997)

Peptide-conjugated PMOs for the treatment of myotonic dystrophy
by: Stoodley, J, et al.
Published: (2022)

Myotonic dystrophy: practical issues relating to assessment of strength.
by: Whittaker, R, et al.
Published: (2006)

Clinical and molecular aspects of the myotonic dystrophies: a review.
by: Machuca-Tzili, L, et al.
Published: (2005)

Three cases of androgen-dependent disease associated with myotonic dystrophy.
by: Cooper, S, et al.
Published: (2003)

Preclinical development of antisense conjugates for the treatment of myotonic dystrophy 1
by: Stoodley, J
Published: (2024)

Application of antisense conjugates for the treatment of myotonic dystrophy type 1
by: Stoodley, J, et al.
Published: (2023)

Alternative isoform regulation in myotonic dystrophy
by: Wang, Eric T. (Eric Tzy-shi)
Published: (2012)

New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC).
by: Ashizawa, T, et al.
Published: (2000)

Hearing impairment in patients with myotonic dystrophy type 2
by: van Vliet, J, et al.
Published: (2018)

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
by: Cerro-Herreros, E, et al.
Published: (2021)

Incorrect diagnosis of myotonic dystrophy and its potential consequences revealed by subsequent direct genetic analysis.
by: Barnes, P, et al.
Published: (1994)

PPMO's as therapeutic modulators for myotonic dystrophy type 1
by: Holland, A, et al.
Published: (2018)

Late-onset cytoplasmic body myopathy resembling myotonic dystrophy.
by: Morris, H, et al.
Published: (1999)

Does cytosine-thymine-guanine (CTG) expansion size predict cardiac events and electrocardiographic progression in myotonic dystrophy?
by: Clarke, N, et al.
Published: (2001)

Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1
by: Holland, A, et al.
Published: (2018)

Proteomic analysis of the function of DMPK, the myotonic dystrophy protein kinase
by: Luciano, Brenda Sierra, 1965-
Published: (2005)

MRC Centre for Neuromuscular Diseases 1st (1st December 2010), and 2nd (2nd May 2012) myotonic dystrophy workshops, London, UK and the myotonic dystrophy standards of care and national registry meeting, Newcastle, UK July 2011
by: Turner, C, et al.
Published: (2013)

MRC Centre for Neuromuscular Diseases 1st (1st December 2010), and 2nd (2nd May 2012) myotonic dystrophy workshops, London, UK and the myotonic dystrophy standards of care and national registry meeting, Newcastle, UK July 2011.
by: Turner, C, et al.
Published: (2013)

Application of CRISPR-Cas9-mediated genome editing for the treatment of myotonic dystrophy type 1
by: Marsh, S, et al.
Published: (2020)

Self reported snoring and daytime sleepiness in men aged 35-65 years.
by: Stradling, JR, et al.
Published: (1991)

Choroidal new vessels in type 1 myotonic dystrophy-related macular dystrophy respond to anti-VEGF therapy.
by: Zinkernagel, MS, et al.
Published: (2012)

Using digital technologies to engage with medical research: views of myotonic dystrophy patients in Japan
by: Coathup, V, et al.
Published: (2016)

Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial.
by: Spathis, A, et al.
Published: (2014)

Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial
by: Spathis, A, et al.
Published: (2014)

Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy
by: Wagner, Stacey D., et al.
Published: (2017)

Sleep restriction therapy for insomnia is associated with reduced objective total sleep time, increased daytime somnolence, and objectively impaired vigilance: implications for the clinical management of insomnia disorder.
by: Kyle, S, et al.
Published: (2014)

Childhood-onset form of myotonic dystrophy type 1 and autism spectrum disorder: Is there comorbidity?
by: Angeard, N, et al.
Published: (2017)

DMPK and myotonic dystrophy : effects of CTG trinucleotide expansion upon DMPK and their contribution to DM pathogenesis
by: Davis, Brigid Michele, 1967-
Published: (2009)

Daytime impairment during sleep restriction therapy for insomnia: Results from a randomised-controlled trial
by: Maurer, LF, et al.
Published: (2019)

Modafinil for multiple sclerosis fatigue: does it work?
by: Littleton, E, et al.
Published: (2010)

Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice
by: Klein, AF, et al.
Published: (2019)

An audit of the use of Modafinil in clinical practice for the treatment of fatigue in multiple sclerosis patients
by: Littleton, E, et al.
Published: (2005)